About Transmembrane protease serine 11D
Transmembrane protease serine 11D (TMPRSS11D) is a protein
from Homo sapiens identified by UniProt accession
O60235, 418 residues long.
MolForge cross-references it against 0 known binders and
292 disease associations.
Target properties
| Protein name | Transmembrane protease serine 11D |
|---|
| UniProt accession | O60235 |
|---|
| Gene | TMPRSS11D |
|---|
| Organism | Homo sapiens |
|---|
| Length | 418 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (292)
Diseases linked to this target (Open Targets).
- acute myeloid leukemia · score 0.09
- non-small cell lung carcinoma · score 0.07
- psoriasis · score 0.07
- acute lymphoblastic leukemia · score 0.06
- melanoma · score 0.06
- Rheumatoid arthritis · score 0.06
- chronic lymphocytic leukemia · score 0.05
- reticulum cell sarcoma · score 0.05
- Ewing sarcoma · score 0.05
- Juvenile Myelomonocytic Leukemia · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O60235-F1 | alphafold | PREDICTED | 90.42 | — |
Amino-acid sequence (418 residues)
MYRPARVTST SRFLNPYVVC FIVVAGVVIL AVTIALLVYF LAFDQKSYFY RSSFQLLNVE YNSQLNSPAT QEYRTLSGRI ESLITKTFKE SNLRNQFIRA HVAKLRQDGS GVRADVVMKF QFTRNNNGAS MKSRIESVLR QMLNNSGNLE INPSTEITSL TDQAAANWLI NECGAGPDLI TLSEQRILGG TEAEEGSWPW QVSLRLNNAH HCGGSLINNM WILTAAHCFR SNSNPRDWIA TSGISTTFPK LRMRVRNILI HNNYKSATHE NDIALVRLEN SVTFTKDIHS VCLPAATQNI PPGSTAYVTG WGAQEYAGHT VPELRQGQVR IISNDVCNAP HSYNGAILSG MLCAGVPQGG VDACQGDSGG PLVQEDSRRL WFIVGIVSWG DQCGLPDKPG VYTRVTAYLD WIRQQTGI
Explore Transmembrane protease serine 11D with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets